Table 1 Summary of BRAF inhibitor trials
From: Therapy for metastatic melanoma: the past, present, and future
| Trial | Patients | RR% |
PFS (months) |
OS (years) |
Number (Patients) | Summary |
|---|---|---|---|---|---|---|
|
Phase 2 Ribas et al. [15] | Vemurafenib in previously treated metastatic melanoma | 52 | 6.2 | Not yet reached | 132 | Met primary end point of best overall survival target of 30% (95% CI: 43 to 61%) |
|
Phase 3 Chapman et al. [16] |
Vemurafenib versus dacarbazine in untreated metastatic melanoma |
48 v 5 |
5.3 v 1.6 | Not yet reached | 675 |
Compared vemurafenib and dacarbazine with co-primary endpoints of overall survival and progression free survival. 84% vs 64% OS at 6 months (95% CI: 78 to 89) |